Women of reproductive age, especially those with obesity
Care Setting
Multidisciplinary clinical management integrating endocrinology, hepatology, cardiology, and metabolic care
Key Highlights
PCOS affects 11–13% of women globally and is a systemic metabolic disorder beyond reproductive dysfunction.
Obese PCOS patients have a 51.61% prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD) and 2–4 fold increased cardiovascular and type 2 diabetes risk.
Multi-organ involvement includes liver steatosis, cardiovascular injury, pancreatic β-cell dysfunction, and muscular sarcopenia driven by shared metabolic pathways.
Guideline-Based Recommendations
Diagnosis
Use 2003 Rotterdam Criteria requiring at least two of: ovulatory dysfunction, clinical/biochemical hyperandrogenism, polycystic ovarian morphology after excluding other causes.
Perform comprehensive metabolic risk assessment including screening for diabetes and dyslipidemia.
Evaluate hepatic steatosis via ultrasound-derived fat fraction (UDFF) in obese PCOS patients.
Management
Adopt integrated, multidisciplinary care addressing reproductive, hepatic, cardiovascular, pancreatic, and muscular health.
Implement lifestyle modifications targeting weight management and insulin sensitivity.
Use insulin sensitizers (e.g., metformin) and hormonal therapies for symptom control.
Target shared pathophysiological pathways such as inflammation and oxidative stress.
Monitoring & Follow-up
Regular cardiovascular risk assessment including waist-to-height ratio and blood pressure monitoring.
Monitor liver function and progression of MASLD in obese PCOS patients.
Screen for type 2 diabetes and pancreatic β-cell function.
Assess muscle strength and signs of sarcopenia.
Risks
Elevated risk of metabolic dysfunction–associated steatotic liver disease (MASLD).
Increased incidence of cardiovascular disease and accelerated atherosclerosis.
Higher risk of type 2 diabetes and pancreatic cancer.
Muscle metabolic impairment leading to sarcopenia and decreased strength.
Patient & Prescribing Data
Women with PCOS, particularly those with obesity and hyperandrogenic phenotypes
Therapies should address systemic metabolic dysfunction including insulin resistance and inflammation; metformin and hormonal agents remain mainstays but require integration with multidisciplinary approaches for multi-organ protection.
Clinical Best Practices
Recognize PCOS as a systemic metabolic disease requiring holistic management beyond reproductive symptoms.
Screen routinely for hepatic, cardiovascular, pancreatic, and muscular complications in PCOS patients.
Employ multidisciplinary teams to coordinate care addressing metabolic, endocrine, and organ-specific risks.
Focus on early intervention to disrupt the vicious cycle of hyperandrogenism and insulin resistance.
Incorporate lifestyle interventions emphasizing weight control and metabolic health.
